These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Cancer immunoprevention: from mice to early clinical trials. Palladini A; Landuzzi L; Lollini PL; Nanni P BMC Immunol; 2018 Jun; 19(1):16. PubMed ID: 29902992 [TBL] [Abstract][Full Text] [Related]
9. Vaccines and other immunological approaches for cancer immunoprevention. Lollini PL; Nicoletti G; Landuzzi L; Cavallo F; Forni G; De Giovanni C; Nanni P Curr Drug Targets; 2011 Dec; 12(13):1957-73. PubMed ID: 21158706 [TBL] [Abstract][Full Text] [Related]
10. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. De Giovanni C; Nicoletti G; Landuzzi L; Croci S; Palladini A; Antognoli A; Murgo A; Ianzano ML; Grosso V; Stivani V; Iezzi M; Musiani P; Nanni P; Lollini PL Vaccine; 2009 Mar; 27(14):2065-9. PubMed ID: 19428831 [TBL] [Abstract][Full Text] [Related]
11. HER-2/neu as a target for cancer vaccines. Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929 [TBL] [Abstract][Full Text] [Related]
12. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini PL; Masucci G; Forni G; Cavallo F Cancer Res; 2010 Apr; 70(7):2604-12. PubMed ID: 20332241 [TBL] [Abstract][Full Text] [Related]
13. Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice. Venanzi FM; Barucca A; Havas K; Capitani M; Provinciali M; Scotti S; Concetti A Vaccine; 2010 May; 28(22):3841-7. PubMed ID: 20350624 [TBL] [Abstract][Full Text] [Related]
14. New approaches to immunoprevention and immunotherapy of neoplasms. Glushkov AN Russ J Immunol; 2002 Oct; 7(3):219-28. PubMed ID: 12674931 [TBL] [Abstract][Full Text] [Related]
15. New target antigens for cancer immunoprevention. Lollini PL; Nicoletti G; Landuzzi L; De Giovanni C; Nanni P Curr Cancer Drug Targets; 2005 May; 5(3):221-8. PubMed ID: 15892621 [TBL] [Abstract][Full Text] [Related]
16. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Knutson KL; Disis ML Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Marshall DJ; Rudnick KA; McCarthy SG; Mateo LR; Harris MC; McCauley C; Snyder LA Vaccine; 2006 Jan; 24(3):244-53. PubMed ID: 16135392 [TBL] [Abstract][Full Text] [Related]
19. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice. Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522 [TBL] [Abstract][Full Text] [Related]
20. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]